Gilead Quarterly Profit Falls as COVID Antiviral Sales Decrease Gilead Quarterly Profit Falls as COVID Antiviral Sales Decrease

Gilead Sciences Inc on Tuesday said its second-quarter adjusted profit fell due to higher research and royalty costs as well as a downturn in sales of its COVID-19 antiviral drug Veklury.Reuters Health Information
Source: Medscape Hiv-Aids Headlines - Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news